EUVIMEDOpdag EUVIMED
BeobachtungsstudieMultizentrische StudieOpen access

Pretreatment HIV Drug Resistance and the Molecular Transmission Network Among HIV-Positive Individuals in China in 2022: Multicenter Observational Study

Hongli Chen iD, Jingjing Hao iD, Jing Hu iD, Chang Song iD, Yesheng Zhou iD, Miaomiao Li iD, Jin Chen iD, Xiu Liu iD, Dong Wang iD, Xiaoshan Xu iD, Peixian Xin iD, Jiaxin Zhang iD and 7 more

JMIR Public Health and Surveillance · 2023-11-17 · 9 · e50894

DOI: 10.2196/50894 ↗

At a glance

Beobachtungsstudie in JMIR Public Health and Surveillance, published online on 2023-11-17. Written by Hongli Chen and 18 co-authors. Institution: National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Beijing, China. Major MEDLINE topics: Anti-HIV Agents, HIV-1, HIV Infections. Cited 34 times so far (Crossref); 49 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Emerging HIV drug resistance caused by increased usage of antiretroviral drugs (ARV) could jeopardize the success of standardized HIV management protocols in resource-limited settings.

Objective

We aimed to characterize pretreatment HIV drug resistance (PDR) among HIV-positive individuals and risk factors in China in 2022.

Methods

This cross-sectional study was conducted using 2-stage systematic sampling according to the World Health Organization’s surveillance guidelines in 8 provincial-level administrative divisions in 2022. Demographic information and plasma samples were obtained from study participants. PDR was analyzed using the Stanford HIV drug resistance database, and the Tamura-Nei 93 model in HIV-TRACE was used to calculate pairwise matches with a genetic distance of 0.01 substitutions per site. Logistic regression was used to identify and estimate factors associated with PDR.

Results

PDR testing was conducted on 2568 participants in 2022. Of the participants, 34.8% (n=893) were aged 30-49 years, 81.4% (n=2091) were male, and 3.2% (n=81) had prior ARV exposure. The prevalence of PDR to protease and reverse transcriptase regions, nonnucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, and protease inhibitors were 7.4% (n=190), 6.3% (n=163), 1.2% (n=32), and 0.2% (n=5), respectively. Yunnan, Jilin, and Zhejiang had much higher PDR incidence than did Sichuan. The prevalence of nonnucleoside reverse transcriptase inhibitor–related drug resistance was 6.1% (n=157) for efavirenz and 6.3% (n=163) for nevirapine. Multivariable logistic regression models indicated that participants who had prior ARV exposure (odds ratio [OR] 7.45, 95% CI 4.50-12.34) and the CRF55_01B HIV subtype (OR 2.61, 95% CI 1.41-4.83) were significantly associated with PDR. Among 618 (24.2%) sequences (nodes) associated with 253 molecular transmission clusters (size range 2-13), drug resistance mutation sites included K103, E138, V179, P225, V106, V108, L210, T215, P225, K238, and A98.

Conclusions

The overall prevalence of PDR in China in 2022 was modest. Targeted genotypic PDR testing and medication compliance interventions must be urgently expanded to address PDR among newly diagnosed people living with HIV in China.

Subjects

MeSH terms (MEDLINE)

Anti-HIV AgentsHIV-1HIV InfectionsHumansMaleFemaleReverse Transcriptase InhibitorsCross-Sectional StudiesChinaDrug Resistance, Viral

Author keywords

HIVhuman immunodeficiency virusmolecular transmission networkmutationpretreatment drug resistancerisk factors

Substances

Reverse Transcriptase InhibitorsAnti-HIV Agents

Authors and institutions

  • National Center for AIDS/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Sichuan Nursing Vocational College, Chengdu, China.
  • Department of Public Health, The University of Texas at San Antonio, San Antonio, TX, United States.

ORCID profiles: Hongli Chen, Jingjing Hao, Jing Hu, Chang Song, Yesheng Zhou, Miaomiao Li, Jin Chen, Xiu Liu, Dong Wang, Xiaoshan Xu, Peixian Xin, Jiaxin Zhang, Lingjie Liao, Yi Feng, Dan Li, Stephen W Pan, Yiming Shao, Yuhua Ruan, Hui Xing

Cite

APA

Chen, H., Hao, J., Hu, J., Song, C., Zhou, Y., Li, M., Chen, J., Liu, X., Wang, D., Xu, X., Xin, P., Zhang, J., Liao, L., Feng, Y., Li, D., Pan, S. W., Shao, Y., Ruan, Y., & Xing, H. (2023). Pretreatment HIV Drug Resistance and the Molecular Transmission Network Among HIV-Positive Individuals in China in 2022: Multicenter Observational Study. JMIR Public Health and Surveillance, 9, e50894. https://doi.org/10.2196/50894

Vancouver

Chen H, Hao J, Hu J, Song C, Zhou Y, Li M, et al. Pretreatment HIV Drug Resistance and the Molecular Transmission Network Among HIV-Positive Individuals in China in 2022: Multicenter Observational Study. JMIR Public Health and Surveillance. 2023;9:e50894. doi:10.2196/50894

BibTeX
@article{Chen2023,
  author = {Chen, Hongli and Hao, Jingjing and Hu, Jing and Song, Chang and Zhou, Yesheng and Li, Miaomiao and Chen, Jin and Liu, Xiu and Wang, Dong and Xu, Xiaoshan and Xin, Peixian and Zhang, Jiaxin and Liao, Lingjie and Feng, Yi and Li, Dan and Pan, Stephen W and Shao, Yiming and Ruan, Yuhua and Xing, Hui},
  title = {Pretreatment HIV Drug Resistance and the Molecular Transmission Network Among HIV-Positive Individuals in China in 2022: Multicenter Observational Study},
  journal = {JMIR Public Health and Surveillance},
  year = {2023},
  volume = {9},
  pages = {e50894},
  doi = {10.2196/50894}
}
Start for free →